Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 3/20 | 0.62 |
| ▸ | CNR1 | P21554 | 5/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | SMO | Q99835 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | CCNC | P24863 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15901016 | 0.87 | NPC1 (0.63) | KDRMAPK1LMNAMAPTNPC1 | |
| SCHEMBL14882746 | 0.85 | KDM4D (0.52) | METCNR1 | |
| SCHEMBL18135104 | 0.84 | GAA (0.56) | METCNR1KDRRAB9ASMN1; SMN2 | |
| SCHEMBL25003152 | 0.84 | MAP4K4 (0.52) | METCNR1KDRLMNAMAPT | |
| SCHEMBL29834818 | 0.83 | KDR (0.67) | METKDRMAPK1ABL1CCNC | |
| SCHEMBL27173842 | 0.83 | KDR (0.67) | METKDRMAPK1ABL1CCNC | |
| SCHEMBL27847068 | 0.82 | CCNC (0.62) | CNR1KDRSMOCCNCCDK8 | |
| SCHEMBL1937813 | 0.81 | RAB9A (0.56) | METCNR1KDRLMNAABL1 | |
| SCHEMBL1938750 | 0.80 | GRM4 (0.55) | CNR1KDRSMOMAPTCCNC | |
| SCHEMBL1939830 | 0.80 | KMO (0.58) | METKDRSMOLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | MET 1552/4885CNR1 1129/4885KDR 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.